DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Phase 1

Completed

Conditions: Adult Anaplastic Astrocytoma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: ixabepilone
Other: pharmacological study
Drug: Anticonvulsant

First Posted Date: 2003-01-27

Last Posted Date: 2017-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00045708

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Recurrent Adult Acute Myeloid Leukemia
Recurrent Melanoma
Stage IV Melanoma
Stage IV Non-small Cell Lung Cancer
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Biological: ipilimumab

First Posted Date: 2003-01-27

Last Posted Date: 2018-09-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00039091

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Stage II Pancreatic Cancer
Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tipifarnib
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 154

Registration Number: NCT00026104

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

Phase 2

Completed

Conditions: Colorectal Cancer
Familial Adenomatous Polyposis

Interventions: Drug: Celecoxib
Other: Placebo
Drug: eflornithine
Other: Laboratory biomarker analysis
Other: Questionnaire administration

First Posted Date: 2003-01-27

Last Posted Date: 2020-09-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 205

Registration Number: NCT00033371

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Phase 2

Completed

Conditions: Hematologic Neoplasms

Interventions: Procedure: Apheresis
Procedure: Stem cell transplantation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Methotrexate
Drug: Cyclosporine

First Posted Date: 2003-01-08

Last Posted Date: 2021-09-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT00051311

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Phase 2

Completed

Conditions: Lupus Membranous Nepropathy
Membranous Glomerulonephritis

First Posted Date: 2002-12-18

Last Posted Date: 2017-10-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 12

Registration Number: NCT00050713

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Recruiting

Conditions: Cutaneous Leiomyoma
Renal Tumor Histology
Kidney Cancer

First Posted Date: 2002-12-18

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1130

Registration Number: NCT00050752

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Voriconazole to Treat Fungal Infections

Phase 3

Completed

Conditions: Mycoses

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00001940

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00001696

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients

Phase 1

Completed

Conditions: Ovarian Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00001272

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy